Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;41(6):718-23.
doi: 10.1038/ng.374. Epub 2009 May 3.

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

Affiliations

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

Mario Capasso et al. Nat Genet. 2009 Jun.

Abstract

We conducted a SNP-based genome-wide association study (GWAS) focused on the high-risk subset of neuroblastoma. As our previous unbiased GWAS showed strong association of common 6p22 SNP alleles with aggressive neuroblastoma, we restricted our analysis here to 397 high-risk cases compared to 2,043 controls. We detected new significant association of six SNPs at 2q35 within the BARD1 locus (P(allelic) = 2.35 x 10(-9)-2.25 x 10(-8)). We confirmed each SNP association in a second series of 189 high-risk cases and 1,178 controls (P(allelic) = 7.90 x 10(-7)-2.77 x 10(-4)). We also tested the two most significant SNPs (rs6435862, rs3768716) in two additional independent high-risk neuroblastoma case series, yielding combined allelic odds ratios of 1.68 each (P = 8.65 x 10(-18) and 2.74 x 10(-16), respectively). We also found significant association with known BARD1 nonsynonymous SNPs. These data show that common variation in BARD1 contributes to the etiology of the aggressive and most clinically relevant subset of human neuroblastoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Summary of the neuroblastoma GWAS results in the discovery set restricted to the high-risk group of patients
The y-axis represents the level of significance for each SNP (log transformed P-values) at the relative genomic position (Build 35) on each chromosome along the x-axis from short arm terminus (left) to long arm terminus (right). The horizontal line indicates our threshold for follow-up analysis (P-value < 1×10−7). The previously reported 6p22 signal is more significant in this discovery case series enriched for the subset of 397 high-risk patients compared to the 1032 unselected neuroblastoma cases previously studied, and a new chromosome 2q35 signal emerged.
Figure 2
Figure 2. Regional plot of the BARD1 locus associated with high-risk neuroblastoma
Single marker results (−log10P-values) for association testing of all SNPs at the BARD1 locus with six SNPs showing P-values <1×10−7 indicated in relation to the BARD1 genomic structure (exons indicated by vertical boxes) and in relation to the r2 linkage disequilibrium structure at all BARD1 SNPs with MAF>0.05 from HapMap CEU data, generated with the use of Haploview software. The position of five additional nsSNPs subsequently genotyped is also indicated (rs7585356 located 3′ downstream of BARD1 was also genotyped but is not shown).

References

    1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. - PubMed
    1. Maris JM, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358:2585–93. - PMC - PubMed
    1. Hero B, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26:1504–10. - PubMed
    1. Nickerson HJ, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol. 2000;18:477–86. - PubMed
    1. Matthay KK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. New England Journal of Medicine. 1999;341:1165–73. - PubMed

Publication types

Substances